TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06154252: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic I

Sponsor: Cabaletta Bio · Phase: PHASE2/PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 74 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$505,080

Rescue Site Savings

+$336,720

Unlock Full NCT06154252 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06154252 Rescue Dossier →